Literature DB >> 11295775

Erythropoietin deficiency and anaemia in multiple system atrophy.

A S Winkler1, J Marsden, M Parton, P J Watkins, K R Chaudhuri.   

Abstract

Serum erythropoietin (EPO) levels are partially controlled by the sympathetic outflow to the kidney. We have studied whether patients with multiple system atrophy (MSA), known to be associated with dysautonomia, are EPO-deficient. Eighteen MSA patients were studied along with 32 idiopathic Parkinson's disease (PD) patients, 23 controls with iron-deficiency anaemia, and 18 healthy individuals. Serum creatinine was normal in all groups. Mean haemoglobin (Hb) concentration in MSA patients was 13.7 +/- 1.7 g/dL. Four MSA patients had unexplained anaemia (minimum Hb: 10.5 g/dL) and abnormal autonomic function tests including significant postural hypotension, whereas none of the PD patients was anaemic. Serum EPO levels were suppressed in relation to anaemia in MSA patients compared to elevated EPO levels in iron-deficiency anaemia patients (difference of regression lines P < 0.001), indicating EPO deficiency in the anaemic MSA patients. Serum EPO levels in PD patients were within normal range. A subset of MSA patients has anaemia and postural hypotension, which may be associated with EPO deficiency. This may have therapeutic implications. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295775     DOI: 10.1002/mds.1063

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 3.  Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Daan C Velseboer; Rob J de Haan; Wouter Wieling; David S Goldstein; Rob M A de Bie
Journal:  Parkinsonism Relat Disord       Date:  2011-05-14       Impact factor: 4.891

Review 4.  Management of multiple system atrophy: state of the art.

Authors:  C Colosimo; D Tiple; G K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

Review 5.  Current pharmacologic treatment for orthostatic hypotension.

Authors:  Roy Freeman
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

Review 6.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

7.  Abnormal baroreceptor-mediated vasopressin release as possible marker in early diagnosis of multiple system atrophy.

Authors:  K Deguchi; I Sasaki; T Touge; M Tsukaguchi; H Takeuchi; S Kuriyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

8.  Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy.

Authors:  Martin Köllensperger; Florian Krismer; Anton Pallua; Nadia Stefanova; Werner Poewe; Gregor K Wenning
Journal:  Mov Disord       Date:  2011-01-06       Impact factor: 10.338

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.